

## ESPGHAN Monothematic Conference: Management of Progressive Liver Diseases

General Information

Programme

Faculty

**Application Deadline:** 07.01.2018

### Registration Fee

Trainee Member Regular Fee (200.00€)

Member Regular Fee (350.00€)

Non-Member Regular fee (450.00€)



**ESPGHAN**  
European Society for Paediatric  
Gastroenterology, Hepatology and Nutrition

**ESPGHAN  
MONOTHEMATIC  
CONFERENCE:  
MANAGEMENT OF PROGRESSIVE  
LIVER DISEASES**

**FEBRUARY 01-03, 2018  
BRUSSELS, BELGIUM**

[www.espghan.org](http://www.espghan.org)

Dear colleagues

It is our great pleasure to invite you to the ESPGHAN monothematic conference on Progressive Liver Disease in the beautiful city of Brussels.

After the success of the two monothematic conference on Cystic Fibrosis related Liver Disease in Paris (January 2016), and the PFIC conference in Budapest the Hepatology Committee of ESPGHAN has decided to continue with organization of focused meetings on important hepatic diseases. Historically chronic injury to the liver results in fibrosis progressing to cirrhosis which ultimately can result in development of hepatocellular carcinoma or can be rescued by liver transplantation. In the past two decades, there has been an exponential increase in the knowledge about the pathogenetic mechanisms leading to fibrosis and recognition that fibrosis can be halted or reversed in some of the progressive liver disease (reversible liver diseases). There remain certain subgroups of liver diseases which inevitably progress to fibrosis/cirrhosis despite modern management (irreversible liver diseases).

The monothematic conference aims to provide an overview of the state-of-the-art knowledge of the pathophysiology of the cellular and immunological mechanisms leading to fibrosis and progression to cirrhosis. The expert speakers will provide an update about the current management of 'reversible liver diseases' and 'irreversible liver diseases' including the complications related to chronic liver diseases in children and young adults.

There will be focused discussion about the potential therapeutic targets for halting the progression of fibrosis in 'irreversible liver disease'. The conference will also provide a platform to further research into current and potential anti-fibrotic therapies and reach our final goal of halting/reversing progression of all liver diseases.

The program will include slots for oral case presentations and attendees will be invited to submit cases for presentation and discussion. The program with speakers and the application forms for case/abstract submission will be available in September 2017. The program will run from 1PM February 1st till 1PM February 3rd, 2018.

Girish Gupte, Françoise Smets, Henkjan Verkade  
Local Organisers

**Early Bird Fess are applicable until December 08 2017. After this deadline the regular fees will be:**

**Trainee - EUR 200**

**Member Fee - EUR 350**

**Non Member Fee - EUR 450**

### **General rules for abstract submission**

Abstract submission opens: 1st November

Abstract submission closes: 15th December

Authors informed about outcome: 2nd January

Authors registration deadline: 9th January

Language : English

Abstract word count : maximum 400

Title length: inclusive in total word count

Tables : maximum 2

Figure maximum 1

Details of authors: presenters name to be included and underlined

Number of coauthors : no restriction

Who can present : no restriction , but any of the coauthors can present but should be registered for the conference can present . Should have a medical / allied health professional background

What can be submitted: completed work with analysis of data and conclusion would be preferable

Trial design abstract may be considered at the discretion of the abstract selection committee

Presenting author of the abstract should be registered for the meeting and full payment should be done prior to the meeting

Abstract should be completed in word document format font size 11 and submitted to the ESPGHAN Office at [office@espghan.org](mailto:office@espghan.org)

It remains the discretion of the organising committee to decide about abstract acceptance

Contact